Skip to main content

Combined Immunodeficiency clinical trials at UCSF
1 in progress, 1 open to new patients

  • EZN-2279 in Patients With ADA-SCID

    open to all eligible people

    The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.

    San Francisco, California and other locations